Verrica Pharmaceuticals Inc. (VRCA): Price and Financial Metrics
GET POWR RATINGS... FREE!
VRCA POWR Grades
- VRCA scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.5% of US stocks.
- The strongest trend for VRCA is in Quality, which has been heading up over the past 178 days.
- VRCA's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).
VRCA Stock Summary
- With a price/sales ratio of 32.53, VERRICA PHARMACEUTICALS INC has a higher such ratio than 95.47% of stocks in our set.
- With a year-over-year growth in debt of -96.48%, VERRICA PHARMACEUTICALS INC's debt growth rate surpasses just 1.12% of about US stocks.
- The volatility of VERRICA PHARMACEUTICALS INC's share price is greater than that of 92.35% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to VERRICA PHARMACEUTICALS INC, a group of peers worth examining would be IPWR, BFLY, ALTR, ASTC, and PLSE.
- Visit VRCA's SEC page to see the company's official filings. To visit the company's web site, go to www.verrica.com.
VRCA Valuation Summary
- VRCA's price/earnings ratio is -12; this is 153.1% lower than that of the median Healthcare stock.
- VRCA's EV/EBIT ratio has moved up 80.1 over the prior 58 months.
Below are key valuation metrics over time for VRCA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VRCA | 2023-03-17 | 32.5 | 7.3 | -12.0 | -11.7 |
| VRCA | 2023-03-16 | 32.9 | 7.4 | -12.2 | -11.9 |
| VRCA | 2023-03-15 | 30.8 | 7.0 | -11.4 | -11.0 |
| VRCA | 2023-03-14 | 31.4 | 7.1 | -11.6 | -11.3 |
| VRCA | 2023-03-13 | 30.0 | 6.8 | -11.1 | -10.7 |
| VRCA | 2023-03-10 | 30.4 | 6.9 | -11.2 | -10.8 |
VRCA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VRCA has a Quality Grade of D, ranking ahead of 15.27% of graded US stocks.
- VRCA's asset turnover comes in at 0.133 -- ranking 235th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows VRCA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.133 | 1 | -0.503 |
| 2021-03-31 | 0.137 | 1 | -0.549 |
| 2020-12-31 | 0.000 | NA | -0.697 |
| 2020-09-30 | 0.000 | NA | -0.639 |
| 2020-06-30 | 0.000 | NA | -0.574 |
| 2020-03-31 | 0.000 | NA | -0.496 |
VRCA Price Target
For more insight on analysts targets of VRCA, see our VRCA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.86 | Average Broker Recommendation | 1.42 (Moderate Buy) |
VRCA Stock Price Chart Interactive Chart >
VRCA Price/Volume Stats
| Current price | $7.12 | 52-week high | $9.22 |
| Prev. close | $6.74 | 52-week low | $1.77 |
| Day low | $6.81 | Volume | 58,000 |
| Day high | $7.20 | Avg. volume | 190,298 |
| 50-day MA | $6.19 | Dividend yield | N/A |
| 200-day MA | $3.76 | Market Cap | 297.99M |
Verrica Pharmaceuticals Inc. (VRCA) Company Bio
Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is based in West Chester, Pennsylvania.
Latest VRCA News From Around the Web
Below are the latest news stories about VERRICA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRCA as an investment opportunity.
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial ResultsNew Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023 VP-102 has potential to address the approximately six million patients in the U.S. with molluscum contagiosum Dosing of first patient in Part 2 of Phase 2 study of VP-315 for treatment of basal cell carcinoma expected in 2Q 2023 Raised gross proceeds of $32.5 million in secondary offering; pro forma cash and cash equivalents to fund planned operations into 1Q 2024 WEST CHESTER, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Verri |
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care ConferenceWEST CHESTER, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will participate in a fireside chat at The Cowen 43rd Annual Health Care Conference, taking place from March 6 - 8, 2023, in Boston, MA. Event details: Date: Monday, March 6, 2023 Time: 2:50 PM - 3:20 PM ET Location: Boston, MA |
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum ContagiosumAssigns PDUFA goal date of July 23, 2023 VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children WEST CHESTER, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interven |
Verrica Pharmaceuticals expects $32.5M from the sale of stock and warrantsThe company last month refiled — for a third time — a new drug application seeking approval for its experimental skin disorder therapy. |
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsWEST CHESTER, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten offering of 750,000 shares of its common stock and pre-funded warrants to purchase 4,064,814 shares of common stock. The shares of common stock are being sold at a price of $6.75 per share and the pre-funded warrants are being sold at |
VRCA Price Returns
| 1-mo | N/A |
| 3-mo | 162.73% |
| 6-mo | 147.22% |
| 1-year | -15.24% |
| 3-year | -17.88% |
| 5-year | N/A |
| YTD | 158.91% |
| 2022 | -69.98% |
| 2021 | -20.42% |
| 2020 | -27.56% |
| 2019 | 94.97% |
| 2018 | N/A |
Loading social stream, please wait...